20/20 BioLabs, Inc. Deal History & Licensing Activity
20/20 BioLabs, Inc. is a life sciences. Over the past three years, 20/20 BioLabs, Inc. has been involved in 1 licensing and acquisition transaction, with a primary focus on Other (2 deals).
Deals (12mo)
1
Active Trials
0
Top Modality
Other
Focus Area
Other
20/20 BioLabs, Inc. Recent Deal Activity
Licensing, acquisition, and partnership transactions involving 20/20 BioLabs, Inc. in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| chronic kidney disease (CKD) prediction algorithm | ROKIT Healthcare Inc. | Other | Approved | license | Mar 2026 |
20/20 BioLabs, Inc. Pipeline Focus
Therapeutic areas and modalities where 20/20 BioLabs, Inc. is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
See How Your Asset Matches 20/20 BioLabs, Inc.'s Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Other assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Other Benchmarks
Upfront, milestone, and royalty benchmarks for other deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About 20/20 BioLabs, Inc. Licensing & Deal Activity
20/20 BioLabs, Inc. is a life sciences company that has been actively engaged in licensing transactions across the biopharma landscape. With 1 deal over the past three years, 20/20 BioLabs, Inc. ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for 20/20 BioLabs, Inc. include Other (2 deals and trials). In terms of modality, 20/20 BioLabs, Inc. has shown particular interest in other.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for 20/20 BioLabs, Inc. and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against 20/20 BioLabs, Inc.'s historical deal terms, or explore all company profiles to find the best partner match for your pipeline.